Medicated effect of CDKN1B on promoting proliferation of islet β cells in diabetes mellitus
10.3760/cma.j.cn101721-20220809-000349
- VernacularTitle:CDKN1B在促进胰岛β细胞增殖中的介导作用
- Author:
Jie LI
1
;
Zhen WANG
;
Ziang LIU
;
Yunfeng LIU
Author Information
1. 山西医科大学第一医院内分泌科，太原 030000
- Keywords:
Diabetes mellitus;
CDKN1B;
Islet β cells
- From:
Clinical Medicine of China
2023;39(3):233-236
- CountryChina
- Language:Chinese
-
Abstract:
The serious decrease in the number of functional β cells is one of the main features in the pathogenesis of diabetes mellitus. CDKN1B is a new kind of regulatory protein, which can bind and inactivate cyclin and cyclin-dependent kinase complex to control the process of cell cycle. It was suggested that down-regulation or deletion of CDKN1B in islet β cells could accelerate the proliferation of islet β cells, thus increasing the number of islet β cells, which is of great significance for treatments of diabetes.
